Thromb Haemost 2006; 96(03): 302-308
DOI: 10.1160/TH06-03-0138
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Identification of a new truncated form and deamidation products of fibrinopeptide B released by thrombin from human fibrinogen

Barbara Cardinali
1   S.S. Proteomica, Istituto Nazionale per la Ricerca sul Cancro, Genova
2   Dipartimento di Chimica e Chimica Industriale, Università di Genova, Genova
,
Gianluca Damonte
3   Dipartimento di Medicina Sperimentale e Centro di Eccellenza per la Ricerca Biomedica, Università di Genova, Genova
,
Luca Melone
3   Dipartimento di Medicina Sperimentale e Centro di Eccellenza per la Ricerca Biomedica, Università di Genova, Genova
,
Annalisa Salis
3   Dipartimento di Medicina Sperimentale e Centro di Eccellenza per la Ricerca Biomedica, Università di Genova, Genova
,
Francesca Tosetti
4   S.C. Oncologia Sperimentale A, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
,
Mattia Rocco
1   S.S. Proteomica, Istituto Nazionale per la Ricerca sul Cancro, Genova
,
Aldo Profumo
1   S.S. Proteomica, Istituto Nazionale per la Ricerca sul Cancro, Genova
› Author Affiliations
Financial support: This study was partially supported by a FIRB RBAU01R5SE grant from the Ministero Università Ricerca Scientifica Tecnologica (MURST), Italy.
Further Information

Publication History

Received 07 March 2006

Accepted after resubmission 17 July 2006

Publication Date:
30 November 2017 (online)

Summary

Quantification of fibrinopeptides release is widely used to investigate fibrinogen activation, and standard chromatographic or capillary electrophoretic procedures are readily available. However, in the analyses of fibrinopeptide mixtures derived from the action of thrombin on human fibrinogen, a few unidentified peaks are usually present. The composition of these peaks was studied by reverse-phase HPLC/MS, revealing a single major anomalous peptide having a molecular mass of 1384.4. A further MS/MS analysis allowed the identification of this form, as a Nterminally truncated fibrinopeptideB (fpB) lacking the first two residues (pyroglutamic acid and glycine). This previously unidentified, relatively low-abundance form (∼7%) has been found consistently in our fibrinopeptides preparations, and analysis of the parent Bβ-chain suggest that it is likely present in circulating fibrinogen. In addition, deamidated forms of all fpB species (including desArgB), resulting from the conversion of asparagine to aspartic acid, were also identified. Overall, these previously unreported forms constitute a substantial amount of fpB (up to ∼17% of the total), and should be taken into account for a reliable quantitative analysis of fpB release.

 
  • References

  • 1 Doolittle RF. The molecular basis of fibrin. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H. editors. The Molecular basis of Blood Diseases. 3rd ed. Saunders; Philadelphia: 2000: 719-39.
  • 2 Blombäck B. Fibrinogen and fibrin: proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
  • 3 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229.
  • 4 Mosesson MW, Doolittle RF. Molecular Biology of Fibrinogen and Fibrin. Annals of the New York Academy of Sciences. Vol. 406. New York: New York Academy of Sciences; 1983
  • 5 Di Cera E, Dang QD, Ayala YM. Molecular mechanisms of thrombin function. Cell Mol Life Sci 1997; 53: 701-30.
  • 6 Kehl M, Lottspeich F, Henschen A. Analysis of human fibrinopeptides by High-Performance Liquid Chromatography. Hoppe-Seyler’s Z Physiol Chem 1981; 362: 1661-4.
  • 7 Profumo A, Turci M, Damonte G. et al. Kinetics of fibrinopeptide release by thrombin as a function of CaCl2 concentration: different susceptibility of FPA and FPB and evidence for a fibrinogen isoform-specific effect at physiological Ca2+ concentration. Biochemistry 2003; 42: 12335-48.
  • 8 Ng AS, Lewis SD, Shafer JA. Quantifying thrombin-catalyzed release of fibrinopeptides from fibrinogen using high-performance liquid-chromatography. In: Methods in Enzymology: Proteolytic enzymes in coagulation, fibrinolysis, and complement activation, Part A. Orlando: Academic Press; 1993. 222: 341-58.
  • 9 Profumo A, Cardinali B, Cuniberti C. et al. Separation of human fibrinopeptides by capillary zone electrophoresis. Electrophoresis 2005; 26: 600-9.
  • 10 Brennan SO. Electrospray ionisation analysis of human fibrinogen. Thromb Haemost 1997; 78: 1055-8.
  • 11 Maghzal GJ, Brennan SO, George PM. The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thromb Res 2005; 115: 293-9.
  • 12 Robinson NE, Robinson AB. Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Natl Acad Sci USA 2001; 98: 4367-72.
  • 13 Robinson NE, Robinson AB. Deamidation of human proteins. Proc Natl Acad Sci USA 2001; 98: 12409-13.
  • 14 Robinson NE. Protein deamidation. Proc Natl Acad Sci USA 2002; 99: 5283-8.
  • 15 Peters B, Trout BL. Asparagine deamidation: pHdependent mechanism from density functional theory. Biochemistry 2006; 45: 5384-92.
  • 16 Spotorno B, Piccinini L, Tassara G. et al. BEAMS (BEAds Modelling System): a set of computer programs for the generation, the visualization and the computation of the hydrodynamic and conformational properties of bead models of proteins. Eur Biophys J 1997; 25: 373-84.
  • 17 Sjöquist J, Blombäck B, Wallén P. Amino acid sequence of bovine fibrinopeptides. Arkiv Kemi 1960; 16: 425-36.